当前位置:首页 > 关于我们 > 创投导师 > 王莉

王莉 | Wang Li


13.jpg

王莉

四川大学华西医院教授,博导

成都华西海圻医药科技有限公司董事长


先后创建了成都华西海圻医药科技有限公司(国家成都新药安全性评价中心)、“国家非人灵长类实验动物繁育基地/四川格林豪斯生物科技有限公司”、“新药临床前有效性评价技术平台/四川康城生物科技有限公司”。构建了中国规模最大的、国际接轨、拥有世界先进坚持装备的“新药临床前安全性评价/有效性评价”高技术服务体系,完成近500个新药项目的中美双边注册申报,为我国生物医药创新成果转化和产业发展做出了重要贡献。承担多项国家科技重大专项,国家高科技发展计划"863"人类重大疾病非人灵长类动物模型研发与应用"项目首席专家,"国家重大新药创制成果转移转化试点示范基地"项目组织者和参与者。

Wang Li

Professor and doctoral advisor of West China Hospital, Sichuan University

Chairman of Chengdu WestChina-Frontier PharmaTech (WCFP).

She has successively founded Chengdu West China-Frontier PharmaTech (WCFP) (National Chengdu new medicine safety evaluation center), "national non-human primate experimental animal breeding base / Sichuan Green-house Biotech Co., Ltd." and "new medicine preclinical effectiveness evaluation technology platform / Sichuan KOBIO Co., Ltd.". Built a high-tech service system of "preclinical safety evaluation / effectiveness evaluation of new medicine" with the largest scale in China, international standards and advanced equipment in the world, and completed the bilateral registration and declaration of nearly 500 new medicine projects between China and the United States, which has made an important contribution to the transformation of China's biomedical innovation achievements and industrial development. She has undertaken a number of major national science and technology projects, as well as the chief expert of "863" plan of R&D and application of non-human primate animal models of major human diseases , and the organizer and participant of" national pilot demonstration base for transfer of major new medicine creation achievements ".


0.181032s